Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus

System; Lupus Erythematosus Clinical Trial

Official title:

Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04970199
• Other study ID #: P.T.REC/012/003252
• Status: Completed
• Phase: N/A
• Start date: July 12, 2021
• Est. completion date: November 30, 2021

Study information

• Verified date: January 2022
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Systemic lupus erythematosus is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in lupus patients affected by disease for more than 5 years is cardiovascular disease due to presence of some factors as oxidative stress, pro-inflammatory cytokines , dyslipidemia, diabetes, and hypertension.

Description:

laser acupuncture (active or sham) for one month (3 days/week ) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian (laser will be applied for 1 min on every acupiont) in lupus females

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: November 30, 2021
• Est. primary completion date: November 10, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 47 Years

Eligibility

Inclusion Criteria:

• lupus females

• 60 patients

Exclusion Criteria:

• pregnancy

• cardiovascular diseases

• respiratory diseases

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• System; Lupus Erythematosus

Intervention

Device:
• laser application on acupoints
laser acupuncture

Locations

Country	Name	City	State
Egypt	Faculty of Physical Therapy Cairo University	Giza	Dokki

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Malondialdehyde	anti-oxidative stress factor	It was measured after 4 weeks
Secondary	systole	blood pressure	It was measured after 4 weeks
Secondary	diastole	blood pressure	It was measured after 4 weeks
Secondary	blood glucose	fasting	It was be measured after 4 weeks
Secondary	erythrocyte sedimentation rate (1 hour)	inflammatory marker	It was measured after 4 weeks
Secondary	erythrocyte sedimentation rate (2 hour)	inflammatory marker	It was measured after 4 weeks
Secondary	c reactive protein	inflammatory marker	It was measured after 4 weeks
Secondary	adenosine triphosphate	energy production marker	It was measured after 4 weeks
Secondary	Nitrate	oxidative stress factor	It was measured after 4 weeks
Secondary	Glutathione	antioxidant marker	It was measured after 4 weeks